{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:47:54Z","timestamp":1788432474400,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for randomization. Tumor board and multidisciplinary review of molecular alterations optimized treatment selection. From 5\/2014 to 4\/2017, 320 patients (median age, 63 years; men, 47%) had tumor molecular aberrations, and 213 (66.56%) received anticancer therapy. The most frequently mutated genes were <jats:italic>TP53<\/jats:italic> (42%), <jats:italic>KRAS<\/jats:italic> (16%), <jats:italic>PIK3CA<\/jats:italic> (12%), and <jats:italic>CDKN2A<\/jats:italic> (11%). The median OS was 10.9 months (95% CI, 8.8\u201312.9). OS was shorter in patients with higher tumor mutational burden. Independent factors associated with shorter OS were age \u226560 years, liver metastases, low albumin levels, high LDH levels, and <jats:italic>KRAS<\/jats:italic> and <jats:italic>TP53<\/jats:italic> mutations. Outcomes for randomized patients will be reported after completion of the study.<\/jats:p>","DOI":"10.1038\/s41698-021-00159-2","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T13:04:20Z","timestamp":1616159060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia Maria","family":"Tsimberidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill S.","family":"Kies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6202-6113","authenticated-orcid":false,"given":"Amber","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"159_CR1","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res. 18, 6373\u20136383 (2012).","journal-title":"Clin. Cancer Res."},{"key":"159_CR2","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","volume":"20","author":"AM Tsimberidou","year":"2014","unstructured":"Tsimberidou, A. M. et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin. Cancer Res. 20, 4827\u20134836 (2014).","journal-title":"Clin. Cancer Res."},{"key":"159_CR3","doi-asserted-by":"crossref","unstructured":"Tsimberidou, A. M. et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. Epub 2017 (2017).","DOI":"10.1200\/PO.17.00002"},{"key":"159_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","volume":"12","author":"AM Tsimberidou","year":"2019","unstructured":"Tsimberidou, A. M. et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J. Hematol. Oncol. 12, 145 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"159_CR5","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","volume":"76","author":"JJ Wheler","year":"2016","unstructured":"Wheler, J. J. et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76, 3690\u20133701 (2016).","journal-title":"Cancer Res."},{"key":"159_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"159_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready, N. et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 37, 992\u20131000 (2019).","journal-title":"J. Clin. Oncol."},{"key":"159_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"159_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","volume":"4","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol. Res. 4, 959\u2013967 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"159_CR10","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"159_CR11","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"159_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"159_CR13","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S1470-2045(15)00397-6","volume":"16","author":"AM Tsimberidou","year":"2015","unstructured":"Tsimberidou, A. M. & Kurzrock, R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 16, e579\u2013e580 (2015).","journal-title":"Lancet Oncol."},{"key":"159_CR14","doi-asserted-by":"crossref","unstructured":"Mangat, P. K. et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis. Oncol. Epub 2018 (2018).","DOI":"10.1200\/PO.18.00122"},{"key":"159_CR15","doi-asserted-by":"publisher","first-page":"djz245","DOI":"10.1093\/jnci\/djz245","volume":"112","author":"KT Flaherty","year":"2020","unstructured":"Flaherty, K. T. et al. The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design [published online ahead of print Janurary 10, 2020]. J. Natl. Cancer Inst. 112, djz245 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"159_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.19.00818","volume":"38","author":"NS Azad","year":"2020","unstructured":"Azad, N. S. et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J. Clin. Oncol. 38, 214\u2013222 (2020).","journal-title":"J. Clin. Oncol."},{"key":"159_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(18)31490-4","volume":"103","author":"K Kalinsky","year":"2018","unstructured":"Kalinsky, K. et al. AZD5363 in patients (Pts) with tumors with AKT mutations: NCI-MATCH subprotocol EAY131-Y, a trial of the ECOG-ACRIN cancer research group (EAY131-Y). Eur. J. Cancer 103, e15 (2018).","journal-title":"Eur. J. Cancer"},{"key":"159_CR18","unstructured":"Clinicaltrials.gov. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial). Accessed August 2020; https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02465060."},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"159_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205\u2013216 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"159_CR21","unstructured":"Tsimberidou, A. M. et al. Preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) study. Eur. Genome-phenome Arch. https:\/\/identifiers.org\/ega.study:EGAS00001004964 (2021)."},{"key":"159_CR22","doi-asserted-by":"publisher","unstructured":"Tsimberidou, A. M. et al. Metadata supporting the article: precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) study. figshare https:\/\/doi.org\/10.6084\/m9.figshare.13643420 (2021).","DOI":"10.6084\/m9.figshare.13643420"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00159-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:49:13Z","timestamp":1670093353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00159-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1038\/s41698-021-00159-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"27 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>Apostolia M. Tsimberidou: Clinical Trial Research Funding<\/b><b><i>(received through the institution)<\/i><\/b> IMMATICS, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, Tvardi, CPRIT; <b><i>Travel, Accommodations, Expenses<\/i><\/b>: ASCO, Genentech, Covance, Tempus; <b><i>Consulting or Advisory Role<\/i><\/b>: Covance, Genentech, Tempus <b>David S Hong Disclosures:<\/b> (last 36 months) <b><i>Research\/Grant Funding (received through the institution):<\/i><\/b> AbbVie, Adaptimmune, Aldi-Norte, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics; <b><i>Travel, Accommodations, Expenses:<\/i><\/b> Bayer, Genmab, AACR, ASCO, P.O.E.T, CCLO, SITC; <b><i>Consulting or Advisory Role:<\/i><\/b> Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity,Liberium, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza Therapeutics, WebMD. <b><i>Other ownership interests:<\/i><\/b> Molecular Match (Advisor), OncoResponse (Founder), Presagia Inc (Advisor) <b>Siqing Fu: Clinical Trial Research\/Grant Funding (Received through the Institution):<\/b> AstraZeneca; Abbisko, Anaeropharma Science; Arrien Pharmaceuticals; BeiGene; BioAtla, LLC; Boehringer Ingelheim; Eli Lilly & Co.; Hookipa Biotech; Huya Bioscience International; IMV, Inc.; Innovent Biologics, Co., Ltd.; MacroGenics; Medivir AB; Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; Novartis; OncoMed Pharmaceuticals; Parexel International, LLC; Sellas Life Sciences Group; Sorcimed Biopharma, Inc.; Tolero Pharmaceuticals; National Institutes of Health\/National Cancer Institute; National Cancer Institute\/National Institutes of Health P30CA016672 \u2013 Core Grant (CCSG Shared Resources) <b>Daniel Dr. Karp: Research\/Grant Funding (received through the institution):<\/b> National Institutes of Health\/National Cancer Institute; Myriad Drug Companies. <b>Consulting or Advisory Role:<\/b> BBLS; Affigen Advisory Board; Black Beret Life Scientist; Phosplatin Therapeutics Advisory Board <b>Sarina A. Piha-Paul: Research\/Grant Funding (Received through the Institution):<\/b> AbbVie, Inc.; ABM therapeutics, Inc; Acepodia, Inc; Alkermes, Inc.; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Chugai Pharmaceutical Co., Ltd; Daichi Sankyo, Inc.; Eli Lilly; Five Prime Therapeutics; Genmab A\/S; GlaxoSmithKline; Helix BioPharma Corp.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Rapt Therapeutics, Inc.; Seattle Genetics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; National Cancer Institute\/National Institutes of Health P30CA016672 \u2013 Core Grant (CCSG Shared Resources) <b>Vinod Ravi: Consulting or Advisory Role:<\/b> Daiichi Sankyo, Inc.; Marvin Health, Inc. <b>Other Ownership Interests:<\/b> UpToDate <b>Vivek Subbiah<\/b>: <b>Research funding\/Grant support for clinical trials (received through the institution):<\/b> Roche\/ Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning point therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy\/ Advisory board: Helsinn, LOXO Oncology\/Eli Lilly, R-Pharma US, INCYTE, QED pharma, Medimmune, Novartis. <b>Other:<\/b> Medscape<b>Shi-Ming Tu: Consulting or Advisory Role<\/b>: Janssen Biotech (Advisor) <b>Filip Janku: Research\/Grant Funding (received through the institution):<\/b> support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Novellus and Proximagen; is or has been on the Scientific Advisory Boards for Bicara, Guardant Health, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. <b>John Heymach: Advisory Committee Participation:<\/b> ARIAD, AstraZeneca, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, Gritstone, GSK, Guardant Health, Eli Lilly, Medivation, Merck, Novartis, Oncomed, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, Synta, Takeda. <b>Clinical Research\/Grant Funding:<\/b> AstraZeneca, GlaxoSmithKline, Spectrum. <b>Royalties and Licensing fees:<\/b> Spectrum. <b>Donald Berry: Other ownership interests:<\/b> co-owner of Berry Consultants, LLC, a company that designs adaptive Bayesian clinical trials for pharmaceutical and medical device companies, National Institutes of Health cooperative groups, international consortia, and patient advocacy groups. <b>David J. Vining: Other ownership interests:<\/b> VisionSR, Majority owner and CEO, multimedia structured reporting for use in advancing medical research; Bracco Diagnostics, Inventor, virtual colonoscopy-related products for colorectal cancer imaging <b>Vincent A. Miller: Patent Royalties:<\/b> Memorial Sloan Kettering Cancer Center, USPO 850141. <b>Stock Holder:<\/b> Foundation Medicine\/ROCHE; EQRX; Mirati Therapeutics. <b>Other Compensation:<\/b> Board of Directors, Revolution Medicines; EQRX Employee <b>Funda Meric-Bernstam: Consulting:<\/b> Aduro BioTech Inc., Alkermes, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, Zymeworks; <b>Advisory Committee:<\/b> Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; <b>Sponsored Research (received through the institution):<\/b> Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co; <b>Honoraria:<\/b> Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey; <b>Other (Travel Related):<\/b> Beth Israel Deaconess Medical Center. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}